Janet L. Kwiatkowski

9.1k citations

173 papers · 4.1k indexed · 2 hit papers · h-index 35

Genetics top 0.1%
- Hemoglobinopathies and Related Disorders 150
- Virus-based gene therapy research 11
Hematology top 0.2%
- Iron Metabolism and Disorders 74
- Blood groups and transfusion 31
Pediatrics, Perinatology and Child Health top 1%
- Prenatal Screening and Diagnostics 25
- Pharmacological Effects and Toxicity Studies 12
Orthopedics and Sports Medicine top 5%
Physiology top 5%
- Erythrocyte Function and Pathophysiology 12
Public Health, Environmental and Occupational Health
- Acute Lymphoblastic Leukemia research 11

Co-authors: Elliott Vichinsky Patricia J. Giardina Ellis J. Neufeld Alexis A. Thompson Nancy F. Olivieri Ellen B. Fung Felicia Trachtenberg Garrett M. Brodeur
Cited by: Genetics Hematology Pediatrics, Perinatology and Child Health
Journals: The Lancet (2 papers)Blood (62 papers)American Journal of Clinical Nutrition (1 paper)
Partner nations: United States United Kingdom Canada

In The Last Decade

Janet L. Kwiatkowski

162 papers receiving 4.0k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Janet L. Kwiatkowski

Since Specialization

Citations

This map shows the geographic impact of Janet L. Kwiatkowski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Janet L. Kwiatkowski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Janet L. Kwiatkowski more than expected).

Fields of papers citing papers by Janet L. Kwiatkowski

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Janet L. Kwiatkowski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Janet L. Kwiatkowski. The network helps show where Janet L. Kwiatkowski may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Janet L. Kwiatkowski, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Janet L. Kwiatkowski Line = papers co-authored together Janet L. Kwiatkowski links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Post-Approval, Real-World Experience with Betibeglogene Autotemcel for Transfusion-Dependent Beta Thalassemia Transplantation and Cellular Therapy ·Nora M. Gibson,David F. Friedman,Caitlin W. Elgarten,Abraham Haimed,Eugene Khandros,Elizabeth Worster,Jonathan G. Bardahl,Lisa Wray,Yongping Wang,Alexis A. Thompson,Janet L. Kwiatkowski,Timothy S. Olson	2025	0
2	Betibeglogene Autotemcel (Beti-cel) Gene Addition Therapy Results in Durable Hemoglobin A (HbA) Production with up to 10 Years of Follow-up in Participants with Transfusion-Dependent β-Thalassemia Transplantation and Cellular Therapy ·Timothy S. Olson,Alexis A. Thompson,Janet L. Kwiatkowski,Jennifer Schneiderman,Isabelle Thuret,Andreas E. Kulozik,Evangelia Yannaki,Marina Cavazzana,Suradej Hongeng,Martin G. Sauer,Adrian J. Thrasher,Ashutosh Lal,John E.J. Rasko,Hancheng Jiang,Tao Ge,Himal L. Thakar,Niki Witthuhn,Mark C. Walters,Franco Locatelli	2025	0
3	Real‐world evidence: Long‐term safety of deferiprone in a large cohort of patients with sickle cell disease enrolled in a registry for up to 10 years American Journal of Hematology ·Janet L. Kwiatkowski,Alexis A. Thompson,Fernando Tricta,Noemi Toiber Temin,Anna Rozova,Caroline Fradette,Sherif M. Badawy	2024	0
4	Neonatal Thrombocytopenia as a Presenting Finding in de novo Pyruvate Kinase Deficiency Neonatology ·Brian M. Dulmovits,K. Taylor Wild,John Flibotte,Michele P. Lambert,Janet L. Kwiatkowski,Christopher S. Thom	2023	0
5	Deferiprone versus deferoxamine for transfusional iron overload in sickle cell disease and other anemias: Pediatric subgroup analysis of the randomized, open‐label FIRST study Pediatric Blood & Cancer ·Mona Hamdy,Amal El‐Beshlawy,Mônica P. A. Veríssimo,Julie Kanter,Baba Inusa,Suzan Williams,David Lee,Noemi Toiber Temin,Caroline Fradette,Fernando Tricta,Fatma Soliman Elsayed Ebeid,Janet L. Kwiatkowski,Mohsen Saleh Elalfy	2023	4
6	Gene addition for beta thalassemia Annals of the New York Academy of Sciences ·Janet L. Kwiatkowski	2023	1
7	Defining the Impacts of Iron Overload in Children Receiving Hematopoietic Stem Cell Transplantation for Non-Malignant Hematologic Conditions Blood ·Nora M. Gibson,Sandra Amaral,Jesse Y. Hsu,Timothy S. Olson,Janet L. Kwiatkowski	2023	0
8	Deferiprone for transfusional iron overload in sickle cell disease and other anemias: open-label study of up to 3 years Blood Advances ·Mohsen Saleh Elalfy,Mona Hamdy,Amal El‐Beshlawy,Fatma Soliman Elsayed Ebeid,Mohamed Badr,Julie Kanter,Baba Inusa,Amira Adly,Suzan Williams,Yurdanur Kılınç,David D. Lee,Caroline Fradette,Anna Rozova,Noemi Toiber Temin,Fernando Tricta,Janet L. Kwiatkowski	2022	16
9	Hemorrhagic Stroke in Children and Adults With Sickle Cell Anemia: The Post-STOP Cohort Stroke ·Christine K. Fox,Liza Leykina,Nancy K. Hills,Janet L. Kwiatkowski,Julie Kanter,John J. Strouse,Jenifer H. Voeks,Heather J. Fullerton,Robert J. Adams,(unknown)	2022	9
10	Safety and Efficacy Outcomes in Pediatric Patients with Transfusion-Dependent β-Thalassemia (TDT) Receiving Betibeglogene Autotemcel (beti-cel; LentiGlobin for β-thalassemia) Gene Therapy in the Phase 3 Hgb-207 (Northstar-2) and Hgb-212 (Northstar-3) Studies Transplantation and Cellular Therapy ·Mark C. Walters,Janet L. Kwiatkowski,John B. Porter,Suradej Hongeng,Evangelia Yannaki,Andreas E. Kulozik,Martin G. Sauer,Adrian J. Thrasher,Isabelle Thuret,Ashutosh Lal,Ruiting Guo,Weijian Liu,Richard A. Colvin,Franco Locatelli,Alexis A. Thompson	2021	1
11	Resolution of Serious Vaso-Occlusive Pain Crises: Results from the Ongoing Phase 1/2 HGB-206 Group C Study of LentiGlobin for Sickle Cell Disease (SCD; bb1111) Gene Therapy Transplantation and Cellular Therapy ·Mark C. Walters,Alexis A. Thompson,Markus Y. Mapara,Janet L. Kwiatkowski,Lakshmanan Krishnamurti,Banu Aygün,Kimberly A. Kasow,Stacey Rifkin-Zenenberg,Manfred Schmidt,Jay DelCarpini,Francis J. Pierciey,Alex Miller,Ren Chen,Sunita Goyal,Julie Kanter,John F. Tisdale	2021	1
12	Efficacy and Safety of Betibeglogene Autotemcel (beti-cel; LentiGlobin for β-thalassemia) Gene Therapy in 60 Patients with Transfusion-Dependent β-Thalassemia (TDT) Followed for up to 6 Years Post-Infusion Transplantation and Cellular Therapy ·Suradej Hongeng,Alexis A. Thompson,Janet L. Kwiatkowski,Franco Locatelli,John B. Porter,John E.J. Rasko,Marina Cavazzana,Martin G. Sauer,Adrian J. Thrasher,Isabelle Thuret,Ashutosh Lal,Andreas E. Kulozik,Evangelia Yannaki,Manfred Schmidt,Ying Chen,Ruiting Guo,Weijian Liu,Richard A. Colvin,Mark C. Walters	2021	1
13	Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study Blood Advances ·Janet L. Kwiatkowski,Mona Hamdy,Amal El‐Beshlawy,Fatma Soliman Elsayed Ebeid,Mohammed Badr,Abdulrahman Alshehri,Julie Kanter,Baba Inusa,Amira Adly,Suzan Williams,Yurdanur Kılınç,David Lee,Fernando Tricta,Mohsen Saleh Elalfy	2021	33
14	Restoring Iron Homeostasis in Pts Who Achieved Transfusion Independence after Treatment with Betibeglogene Autotemcel Gene Therapy: Results from up to 7 Years of Follow-up Blood ·Alexis A. Thompson,Franco Locatelli,Evangelia Yannaki,Mark C. Walters,John B. Porter,Suradej Hongeng,Andreas E. Kulozik,Martin G. Sauer,Adrian J. Thrasher,Isabelle Thuret,Ashutosh Lal,Marina Cavazzana,John E.J. Rasko,Lin Du,Richard A. Colvin,Janet L. Kwiatkowski	2021	2
15	American Society of Hematology 2020 guidelines for sickle cell disease: transfusion supportbreakdown → Blood Advances ·Stella T. Chou,Mouaz Alsawas,Ross M. Fasano,Joshua J. Field,Jeanne E. Hendrickson,Jo Howard,Michelle Kameka,Janet L. Kwiatkowski,France Pirenne,Patricia A. Shi,Sean R. Stowell,Swee Lay Thein,Connie M. Westhoff,Trisha E. Wong,Elie A. Akl	2020	268
16	Favorable Outcomes in Pediatric Patients in the Phase 3 Hgb-207 (Northstar-2) and Hgb-212 (Northstar-3) Studies of Betibeglogene Autotemcel Gene Therapy for the Treatment of Transfusion-Dependent β-Thalassemia Blood ·Alexis A. Thompson,Janet L. Kwiatkowski,John B. Porter,Suradej Hongeng,Evangelia Yannaki,Andreas E. Kulozik,Martin G. Sauer,Adrian J. Thrasher,Isabelle Thuret,Ashutosh Lal,Ruiting Guo,Weijian Liu,Richard A. Colvin,Mark C. Walters,Franco Locatelli	2020	7
17	Long-Term Efficacy and Safety of Betibeglogene Autotemcel Gene Therapy for the Treatment of Transfusion-Dependent β-Thalassemia: Results in Patients with up to 6 Years of Follow-up Blood ·Janet L. Kwiatkowski,Mark C. Walters,Suradej Hongeng,Franco Locatelli,John E.J. Rasko,Marina Cavazzana,Ying Chen,Richard A. Colvin,Alexis A. Thompson	2020	8
18	Safety of Deferiprone in Individuals with Sickle Cell Disease Blood ·Janet L. Kwiatkowski,Fernando Tricta,Anna Rozova	2017	2
19	Results Update from the DRIVE PK Study: Effects of AG-348, a Pyruvate Kinase Activator, in Patients with Pyruvate Kinase Deficiency Blood ·Rachael F. Grace,D. Mark Layton,Frédéric Galactéros,Christian Rosé,Wilma Barcellini,D. Holmes Morton,Eduard J. van Beers,Hassan M. Yaish,Yaddanapudi Ravindranath,Kevin H.M. Kuo,Sujit Sheth,Janet L. Kwiatkowski,Bruce A. Silver,Charles Kung,Marvin B. Cohen,Hua Yang,Penelope A. Kosinski,Lei Hua,Ann Barbier,Bertil Glader	2017	2
20	Acute Silent Cerebral Ischemic Events in Children With Sickle Cell Anemia JAMA Neurology ·Charles T. Quinn,Robert C. McKinstry,Michael M. Dowling,William S. Ball,Michael A. Kraut,James F. Casella,Nomazulu Dlamini,Rebecca Ichord,Lori C. Jordan,Fenella J. Kirkham,Michael J. Noetzel,E. Steve Roach,John J. Strouse,Janet L. Kwiatkowski,Deborah Hirtz,Michael R. DeBaun	2012	48

About Janet L. Kwiatkowski

Janet L. Kwiatkowski is a scholar working on Genetics, Hematology and Pediatrics, Perinatology and Child Health, having authored 173 papers that have together received 4.1k indexed citations. Recurring topics across this work include Hemoglobinopathies and Related Disorders (150 papers), Iron Metabolism and Disorders (74 papers), Blood groups and transfusion (31 papers), Prenatal Screening and Diagnostics (25 papers), Erythrocyte Function and Pathophysiology (12 papers), Pharmacological Effects and Toxicity Studies (12 papers), Virus-based gene therapy research (11 papers) and Acute Lymphoblastic Leukemia research (11 papers). The work is most often cited by research in Genetics (3.0k citations), Hematology (2.4k citations) and Pediatrics, Perinatology and Child Health (836 citations). Janet L. Kwiatkowski has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Elliott Vichinsky, Patricia J. Giardina, Ellis J. Neufeld, Alexis A. Thompson, Nancy F. Olivieri, Ellen B. Fung, Felicia Trachtenberg, Garrett M. Brodeur, Kim Smith‐Whitley and Yeşim Aydınok. Their work appears in journals such as The Lancet, Blood and American Journal of Clinical Nutrition.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact